"These drugs are incredibly expensive," and there is no evidence that they are helpful in any but the rare cancers with specific biomarkers, Dr. Schnipper said.
"We can use biomarkers to identify patients who might have a good response – and also to identify patients who are not appropriate for these drugs," he said. "This is a good example of doing less while still maintaining a high quality of care."
Dr. Schnipper had no financial disclosures.